Clera Inc. is a pharmaceutical company focused on the discovery and development of novel small-molecule therapies for the diagnosis and treatment of major central nervous system disorders. The company¹s lead molecule, CLR151, is currently being optimized as a drug candidate to treat schizophrenia and psychosis. The Company has also identified a pipeline of novel small molecule drug candidates that have potential in the treatment of depression and Parkinson¹s disease as well as a novel diagnostic agent for central nervous system disorders. Clera was founded in 2001 to commercialize discoveries by Dr. Philip Seeman. Based on over 40 years of receptor-based drug discovery research by Dr. Seeman, Clera has designed a portfolio of promising small molecule drug candidates targeting a range of CNS indications. Dr. Seeman discovered the D2 receptor in the mid-1970s. The D2 receptor is the principal target for all antipsychotic drugs; sales of antipsychotic drugs targeting this receptor currently exceed US$14B in combined world-wide revenue annually.